Mereo BioPharma Group plc (AIM:MPH)
London flag London · Delayed Price · Currency is GBP · Price in GBX
26.50
-0.50 (-1.85%)
At close: Dec 17, 2020

Mereo BioPharma Group Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-0.5-10-49.37
Revenue Growth
------
Gross Profit
-00.37-7.431.1525.13
Operating Income
-33.07-38.26-45.72-27.14-52.7-28.35
Net Income
-28.1-41.88-43.25-29.47-42.2217.23
Earnings Per Share
-0.18-0.26-0.29-0.22-0.35-0.31
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
30.1240.9969.857.4268.18127.68
Total Debt
1.030.26.435.9515.3722.69
Net Cash (Debt)
29.0940.7963.3751.4752.81104.99
Net Cash Growth
-47.61%-35.63%23.13%-2.54%-49.70%1289.80%
Net Cash Per Share
0.180.260.430.390.440.95

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-25.35-30.97-32.83-21.13-48.82-7.09
Capital Expenditures
--0.02---0.01-0.72
Free Cash Flow
-25.35-30.99-32.83-21.13-48.83-7.82
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-73.40%-74.26%-50.89%
Operating Margin
--7651.40%--271.36%--57.42%
Pretax Margin
--8375.60%--299.98%-39.05%
Profit Margin
--8375.60%--294.66%-34.90%
FCF Margin
--6198.20%--211.32%--15.83%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-----10.09
PS Ratio
-132.62-32.34-3.52